ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $1,703,073 | +113287.0% | 36,919 | -1.5% | 0.02% | -13.0% |
Q1 2023 | $1,502 | -99.9% | 37,467 | +4.9% | 0.02% | -28.1% |
Q3 2022 | $1,480,000 | +51.3% | 35,729 | +118.0% | 0.03% | +23.1% |
Q2 2022 | $978,000 | +162.2% | 16,391 | +270.0% | 0.03% | +333.3% |
Q4 2021 | $373,000 | -88.4% | 4,430 | -87.6% | 0.01% | -88.5% |
Q3 2021 | $3,228,000 | +113.5% | 35,789 | +125.7% | 0.05% | +79.3% |
Q2 2021 | $1,512,000 | -38.3% | 15,857 | -10.5% | 0.03% | -58.0% |
Q4 2020 | $2,452,000 | +86.6% | 17,712 | +10.8% | 0.07% | +21.1% |
Q3 2020 | $1,314,000 | +57.6% | 15,985 | +49.9% | 0.06% | +39.0% |
Q2 2020 | $834,000 | +37.2% | 10,667 | -25.0% | 0.04% | +95.2% |
Q3 2019 | $608,000 | +41.4% | 14,214 | +124.1% | 0.02% | +61.5% |
Q1 2017 | $430,000 | +83.0% | 6,343 | +159.9% | 0.01% | +62.5% |
Q3 2015 | $235,000 | – | 2,441 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |